MJ has been shown to cleave HK1 and HK2 from VDAC in a dose-dependent manner in the mitochondrial fraction of CT-36 mouse colon carcinoma cells, MOLT-4 human leukemia, BCL1 mouse leukemia, B16 mouse melanoma and HCC hepatocellular carcinoma (LM3, BEL-7402, Hep3B, SMMC-7721). This evidence concerns the gene HK1 and hepatocellular carcinoma.